Amid the ongoing diplomatic row between India and Canada, the Ministry of External Affairs on Thursday said that no information has been shared by Canada regard
Mumbai (Maharashtra) [India], February 21 (ANI/PRNewswire): Entigrity, a leading offshore staffing partner for accounting firms in the U.S., U.K., and Canada, has been honored with the prestigious 'Dream Companies to Work For' and 'Best Employer Brand' Award by World HRD Congress held in Mumbai, India. This esteemed recognition highlights Entigrity's exceptional commitment to delivering top-notch offshoring accounting services and providing a supportive and empowering workplace for its employees. "We are proud to have been recognized as a 'Global Best Employer Brand' and 'Dream Companies to Work For' by the World HRD Congress," said Shwan Parikh, Founder and Chairman of Entigrity. He added further, "Our commitment to creating a supportive and empowering workplace for our employees is at the heart of everything we do, and this recognition is a testament to our efforts. We look forward to continued success in the future." With over
- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco - For people with early Alzheimer's (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months ABERDEEN, Scotland and SINGAPORE, Dec. 1, 2022 /PRNewswire/ TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage clinical trials for a potential therapy designed to target the Tau pathology of Alzheimer's. Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. As a hallmark of the disease, it is recognised as a key target for disease modifying treatments. This approach by TauRx contrasts to many in t